Literature DB >> 19021129

The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients.

Sanne B Schagen1, Enny Das, Frits S A M van Dam.   

Abstract

OBJECTIVE: Many cancer patients report cognitive changes following chemotherapy. In social psychology, there is ample evidence that psychological and physical complaints can increase with increased accessibility of relevant schemata. The accessibility of related concepts in memory may be facilitated through priming or by pre-existing knowledge, resulting in an increase of reported complaints. We examined whether pre-existing knowledge of chemotherapy-associated cognitive problems and priming the 'chemo-brain' schema increase the reporting of cognitive complaints.
METHODS: Two hundred and sixty-one breast cancer patients were interviewed about cognitive problems and other cancer-related symptoms. Preceding the interview, half of the patients were primed with an introduction letter to the study in which the occurrence of cognitive complaints and its relation with chemotherapy was explicated. The remaining patients received a neutral letter that did not mention this relationship.
RESULTS: Patients with pre-existing knowledge about chemotherapy-associated cognitive problems reported more cognitive complaints (M=3.04) than patients without this knowledge (M=2.21; p<0.001). The priming letter increased the reporting of cognitive complaints only for patients without a history of chemotherapy (p<0.05). All effects were independent of negative affect, age and education level.
CONCLUSION: Our study shows that facilitating the accessibility of concepts related to chemotherapy-associated cognitive complaints directly increases the reporting of such complaints, in particular in patients without firsthand chemotherapy experience. This increase in prevalence of cognitive complaints following a chronically or temporarily accessible 'chemo-brain' schema has relevant implications for clinical practice and for scientific research in this area.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19021129     DOI: 10.1002/pon.1454

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  16 in total

1.  Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.

Authors:  Brenna C McDonald; Susan K Conroy; Dori J Smith; John D West; Andrew J Saykin
Journal:  Brain Behav Immun       Date:  2012-05-18       Impact factor: 7.217

2.  Is chemotherapy associated with cognitive impairment?

Authors:  Robert Zachariae; Mimi Yung Mehlsen
Journal:  Nat Rev Urol       Date:  2011-04       Impact factor: 14.432

3.  The perceptions of Australian oncologists about cognitive changes in cancer survivors.

Authors:  Kate Smidt; Lynette Mackenzie; Haryana Dhillon; Janette Vardy; Joanne Lewis; Siew Yim Loh
Journal:  Support Care Cancer       Date:  2016-06-20       Impact factor: 3.603

Review 4.  Broadening the cancer and cognition landscape: the role of self-regulatory challenges.

Authors:  Jamie Arndt; Enny Das; Sanne B Schagen; Stephanie A Reid-Arndt; Linda D Cameron; Tim A Ahles
Journal:  Psychooncology       Date:  2013-07-10       Impact factor: 3.894

5.  Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer.

Authors:  John D Merriman; Bradley E Aouizerat; Janine K Cataldo; Laura Dunn; Bruce A Cooper; Claudia West; Steven M Paul; Christina R Baggott; Anand Dhruva; Kord Kober; Dale J Langford; Heather Leutwyler; Christine S Ritchie; Gary Abrams; Marylin Dodd; Charles Elboim; Deborah Hamolsky; Michelle Melisko; Christine Miaskowski
Journal:  Cytokine       Date:  2013-12-04       Impact factor: 3.861

6.  Stress, coping and cognitive deficits in women after surgery for breast cancer.

Authors:  Stephanie A Reid-Arndt; Cathy R Cox
Journal:  J Clin Psychol Med Settings       Date:  2012-06

7.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

8.  Preliminary evidence of an association between an interleukin 6 promoter polymorphism and self-reported attentional function in oncology patients and their family caregivers.

Authors:  John D Merriman; Bradley E Aouizerat; Dale J Langford; Bruce A Cooper; Christina R Baggott; Janine K Cataldo; Anand Dhruva; Laura Dunn; Claudia West; Steven M Paul; Christine S Ritchie; Patrick S Swift; Christine Miaskowski
Journal:  Biol Res Nurs       Date:  2013-03-11       Impact factor: 2.522

Review 9.  Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review.

Authors:  Ashley Henneghan
Journal:  Support Care Cancer       Date:  2015-09-29       Impact factor: 3.603

10.  Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia.

Authors:  Yin Ting Cheung; Maung Shwe; Earl Hsien Jie Tan; Wai Keung Chui; Raymond Ng; Alexandre Chan
Journal:  J Cancer Surviv       Date:  2013-02-08       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.